anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a sgRNA for targeted knocking-out chicken TRIM45 gene, a TRIM45 knocking-out cell line and application thereof, wherein the nucleotide sequence of the sgRNA is shown as SEQ ID NO. 2. The invention designs a sgRNA of a first exon of a specific targeting TRIM45, and the TRIM45 gene of chicken fibroblasts is successfully knocked out by a CRISPR-Cas9 technology. The detection of protein and mRNA expression proves that the construction of the knocked-out cells is successful, and although the morphology of the TRIM45 knocked-out cells is not obviously changed, the contact inhibition capability is obviously weakened, and the stable passage TRIM45 knocked-out chicken-derived cell line is obtained for the first time. The TRIM45 knockout cell line constructed by the invention obviously enhances the replication level of ALV-J at different infection time points, and can be used for improving the antigen expression quantity of future ALV-J vaccines. The TRIM45 knockout cell line constructed by the invention can also obviously inhibit the replication level of IBDV, is a cell line with IBDV resistance phenotype, and provides biological materials for research on pathogenic mechanism of IBDV and antiviral breeding.
The present invention is in the field of healthcare. More specifically, the invention relates to hexapeptide of formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof and an aqueous pharmaceutical compositions thereof for use in the treatment of an interleukin-6 related respiratory disease by pulmonary administration to a mammal in need thereof. Preferably, the pharmaceutically acceptable salt is H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH diacetate. Preferably, the composition is administered pulmonary in form of aerosol having particle size from 1 to 5 microns. Further, the invention relates to a method of treating an interleukin-6 related respiratory disease, which comprises a step of pulmonary administration of an effective amount of a hexapeptide of formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof to a mammal in need thereof. Preferably, the effective amount of a hexapeptide of formula (I) or a pharmaceutically acceptable salt thereof is from 0.001 to 1.000 mg/kg per kg body weight of the mammal. Preferably, the interleukin-6 related respiratory disease is selected from the group consisting of acute respiratory distress syndrome, acute lower respiratory infection, pneumonia, pulmonary edema, bronchitis, tracheobronchitis, chronic obstructive pulmonary disease, and asthma.
The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
Progressive physical fitness and posture exercises were given via telerehabilitation 3 days a week for 8 weeks. Specific exercises for upper extremities, lower extremities, neck, trunk and lower back were selected and progressed by changing the frequency, duration and variety within the program. All exercises were performed under the supervision of a physiotherapist during video conference calls lasting an average of 40 minutes. Correct sitting and standing positions and ergonomic materials were also explained in detail. Participants' adherence to the exercise program was tracked by an exercise diary.
A synthetic bulk laxative which comprises a crosslinked graft polymer. It is formed of a hydrophilic monomer partially neutralised upto 75 %, a polysaccharide gum upto 3 % by weight and a crosslinker upto 2 % by weight.  The weight percentages are with respect to the hydrophilic monomer. A process for the preparation of the synthetic bulk laxative which comprises upto 75 %  partial neutralisation of a hydrophilic monomer with an alkali. The partially neutralised hydrophilic monomer is polymerised with upto 2 % by weight of a cross linker and upto 3 % by weight of a polysaccharide gum in the presence of an initiator in an organic solvent under inert atmosphere at 30 - 80 ~C. The synthetic bulk laxative is dried at 30 - 120 ~C and pulverised. A formulation of the synthetic bulk laxative in combination with pharmaceutically acceptable excipients.
Adult patients with T1DM or T2DM with any form of diabetic retinopathy and diabetic macular edema, indicated for ocular surgical procedure as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
Antirachitic preparations having special efficacy for chickens are obtained by extracting the fatty matter of invertebrate animals (other than members of the family Helicidae), the sterol fraction of which contains a provitamin-D sterol to the extent of at least 0,25 per cent, removing the unsaponifiable fraction and irradiating it with ultraviolet light.  Invertebrates of the following classes or phyla are treated in the manner described examples of each being given: Porifera (sponges), ichinodermata (starfish), annelida (earthworm, leech), mollusca (slug, oyster, whelk, squid), arthropoda (lobster, mealworm, locust, pupa of silkworm, bee).  According to a suitable method of preparation the raw material is comminuted, if desired with sand, sodium sulphate, alcohol or acetone, and dried in vacuo.  The fat is then extracted with solvents such as ether or petrol-ether, halogen containing solvents being preferably avoided. The fat is saponified in usual manner, e.g. by alcoholic soda or potash, the soap solution being freed from part of the alcohol by distillation and the unsaponifiable fraction separated by dilution with water and extracting or by precipitating lime soaps by treating with a lime salt and extracting the unsaponifiable constituents precipitated with the lime soaps.  The sterol fraction may be purified by recrystallization from alcohol and methyl alcohol. Reference has been directed by the Comptroller to Specification 236,197,* [Class 2 (iii)].
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention describes acylated aminoalkylimidazoles of the general formula (I)   where R 1  means phenyl group possibly monosubstituted with halogen atom or 1-naphthyl group; R 2  means hydrogen atom; or R 1  is hydrogen atom and R 2  is pyridyl or 2-(5-chloro)-pyridyl group; R 3  is halogen atom or C 1-4 -alkoxy-group. Described compounds can be in free form or in the form of salts. Compounds of the formula (I) show capability to inhibit activity of 25-hydroxy-vitamin D 3  hydroxylase selectively. Invention describes also method of their synthesis and pharmaceutical composition based on compound of the formula (I). EFFECT: improved method of synthesis, valuable biochemical properties of compounds. 6 cl, 12 ex
Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The International Society for STD Research (ISSTDR) STI/HIV 2023 World Congress convened a participatory designathon to engage attendees in a problem-solving crowdsourcing event with the mission to design innovative solutions for improving sexually transmitted infection (STI) control. Designathons are three-phase crowdsourcing events consisting of a pre-planning phase, an active and intensive collaborative phase, and denouement phase for implementation and dissemination. Given escalating STI concerns, the Congress organisers recognised the opportunity to harness the collective expertise of the attendees by actively engaging them to generate innovative solutions for STI control by hosting a designathon during the scientific meeting. Designathon activities occurred during the Congress, and innovative solutions were presented during the closing plenary. Organisers prioritised participant diversity and engagement by creating four distinct groups based on lived experiences (Silver, Early Career, Traveller, and Community). Although competing priorities through the Congress were a challenge, participation from the attendees was high. Dedicated time and space for the event allowed for a successful designathon event, and the lack of restrictions, as might be encountered from funders or other stakeholder agencies, allowed participants to creatively develop innovative solutions for STI control. This designathon serves as an exemplar for successfully hosting a designathon at a large scientific meeting to engage attendees and contribute their intellect and voice to collectively solving significant problems.
Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m\^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
BACKGROUND: The increased hypertonicity or activity of pelvic floor muscles can lead to chronic pelvic pain (CPP). It represents an aspecific and persistent pain with no apparent clinical reason, affecting an estimated 6% to 16% of women worldwide. This study aimed to evaluate with validated questionnaires the efficacy and the safeness of a new device that uses Top flat Magnetic Stimulation for the management of muscular hypertonia in women with CCP.
METHODS: All patients underwent 8 treatments with a non-invasive electromagnetic therapeutic device. The device produces a TOP Flat Magnetic Stimulation with a uniform profile so, the muscle work aims to reduce pain while also inhibiting muscle activity. The PISQ-12 questionnaire was used for the evaluation of improvements. Side effects were monitored.
RESULTS: The PISQ-12 total mean score decreases from 29,2 (±3.3) to 17 (±2). Regarding the behavioural-emotive items (1-4), a decrease from 12 (±2) to 7 (±0.9) was visible. Physical items (5-9) decrease from 10,6 (±1.8) to 6 (±1.4) and the Partner Related items (10-12) from 6,6 (±1.6) to 3,9 (±0.4).  Conclusions: The device we used in this research demonstrated to be a valid solution for the treatment of chronic pelvic pain in female patients.
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system, and the exact mechanism of HCC is still unclear. Transcription factor 7 like 2 (TCF7L2) plays a pivotal role in cell proliferation and stemness maintenance. However, the exact mechanism of TCF7L2 in HCC remains unclear.
METHODS: Clinical samples and public databases were used to analyze the expression and prognosis of TCF7L2 in HCC. The function of TCF7L2 in HCC was studied in vitro and in vivo. ChIP and luciferase assays were used to explore the molecular mechanism of TCF7L2. The relationship between TCF7L2 and NEDD9 was verified in HCC clinical samples by tissue microarrays.
RESULTS: The expression of TCF7L2 was upregulated in HCC, and high expression of TCF7L2 was associated with poor prognosis of HCC patients. Overexpression of TCF7L2 promoted the metastasis of HCC in vitro and in vivo, while Knockdown of TCF7L2 showed the opposite effect. Mechanically, TCF7L2 activated neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) transcription by binding to the -1522/-1509 site of the NEDD9 promoter region, thereby increasing the phosphorylation levels of AKT and mTOR. The combination of TCF7L2 and NEDD9 could distinguish the survival of HCC patients.
CONCLUSIONS: This study demonstrated that TCF7L2 promotes HCC metastasis by activating AKT/mTOR pathway in a NEDD9-dependent manner, suggesting that potential of TCF7L2 and NEDD9 as prognostic markers and therapeutic targets for HCC.
People living with HIV (PLWH) are living longer and are becoming increasingly susceptible to multi-morbidity resulting in disability. Physiotherapy is an important component in the care of PLWH, increasing functional capacity and quality of life. However, few PLWH access physiotherapy services due to a lack of specialised services, relapses in medical conditions and financial barriers. This study aimed to gather feedback from PLWH in a tertiary infection centre in Ireland attending out-patient physiotherapy on their experiences of physiotherapy. Eleven PLWH completed a semi-structured feedback survey focusing on their expectations and experiences of physiotherapy. Participants reported an overall positive experience of physiotherapy especially in terms of improving movement, confidence, physical activity level and sense of control. In addition, participants highlighted the importance of a physiotherapist with specialist knowledge of HIV. Barriers to participation in physiotherapy included potential relapses in other medical conditions, lack of time due to work and lack of flexibility or availability of physiotherapy appointments. This study highlights the important role of physiotherapy in the care of PLWH, several potential barriers to participation in physiotherapy for PLWH and the importance of the participation of PLWH in the co-design of services.
PROBLEM TO BE SOLVED: To obtain a novel drug delivery agent of which the capability for accumulating a drug at an objective site can be enhanced by the change in temp. by forming a block copolymer having a polymer block comprising repeating acrylamide deriv. units and a polymer block comprising specific repeating units. SOLUTION: For instance, a polymer having functional group at its one molecular end and represented by formula III [wherein A is a chain comprising repeating acrylamide deriv. units represented by formula I (wherein R<1> and R<2> are each H or an alkyl; and (m) is an integer of 5-500); and X is an alkyl or phenyl group substd. by an amino or carboxyl group, etc.] is reacted with a polymer having a functional group at its one molecular end and represented by formula IV  wherein B is a chain comprising repeating units represented by formula II [wherein R<3> is H, a halogen, or a lower alkyl;  Z is an optionally substd. phenyl group, a lower alkyl, an alkoxy, cyano, or a COOR<4> (wherein R<4> is H or a hydrocarbon group); and (n) is an integer of 1-500]; and Y is a substd. alkyl or phenyl} to give an AB-type block copolymer having a polymer block comprising repeating units represented by formula I and a polymer block comprising repeating units represented by formula II.
PURPOSE: To analyze the risk factors for the relapse of prostate cancer (PC) after radical prostatectomy (RP) and build a nomogram as a predictive model.  Materials andMethods: The patients who underwent PR from March 2019 to February 2022 were retrospectively enrolled in our hospital's case system. During the follow-up process, two consecutive prostate-specific antigens (PSA) ≥0.2 μg/L were performed. And needle biopsy was performed to further determine whether the patient had prostate cancer recurrence. According to the follow-up results, the patients were divided into non-relapsed and relapsed groups.The related parameters of the two groups were collected. Independent risk factors for postoperative recurrence were determined using a Cox proportional hazards regression model. Statistical software, R, was used to build nomograms. R software was used to construct a nomogram, and the prediction effect of the nomogram was evaluated by the calibration curve and the area under the ROC curve (AUC).
RESULTS: Among the 367 patients who underwent RP, 112 (30.52%) had, and 255 (69.48%) did not have relapses after surgery. Cox multivariableregression analysis revealed that preoperative Gleason score, preoperative PSA, pathological staging, positive margin, and seminal vesicle invasion, were the risk factors for postoperative recurrence after RP (all P < 0.05). Verification of the predictive model by ROC curve demonstrated that the AUC of the ROC curves for patients' relapses 3 and 5 years after RP was 0.986 (95%CI0.975-0.998) and 0.974 (95%CI0.961-0.987), respectively. This model validation showed that the results of the predictive model were basically consistent with the actual results, suggesting that the nomogram was able to accurately predict a patient's relapse.
CONCLUSION: The nomogram of this study was a good predictor of postoperative recurrence of PC after RP, which will help doctors provide personalized treatment and follow-up strategies for patients.
PROBLEM TO BE SOLVED: To provide poly(β-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester).SOLUTION: Poly(β-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Because of the poly(amine) nature of these polymers, they are particularly suited for the delivery of polynucleotides. Nanoparticles containing polymer/polynucleotide complexes are prepared. The polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents, given their ability to buffer the pH of their surroundings.
The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
PCT No. PCT/EP95/03370 Sec. 371 Date Apr. 18, 1997 Sec. 102(e) Date Apr. 18, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06940 PCT Pub. Date Mar. 7, 1996A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.
The invention discloses an oral preparation for treating asthma, namely a montelukast sodium capsule and a preparation method thereof. The montelukast sodium capsule consists of a capsule shell and a content. According to the oral preparation disclosed by the invention, montelukast sodium is suspended in hydrophobic excipient oil, so that a protective film is formed around the montelukast sodium; therefore, active ingredients are effectively prevented from getting into contact with water and oxygen in air, so that a relatively stable state is achieved. The montelukast sodium capsule disclosed by the invention is beautiful in appearance and convenient for children and old people to take. The preparation process of the preparation is simple and is low in production cost. In addition, the stability of the preparation in production and storage processes is enhanced.
This group will have placebo capsule and fish oil capsule. Placebo capsule contained maltodextrin and magnesium stearate, while fish oil contained EPA 350mg + DHA 250mg. The participants will receive the supplements for a period of 6 months and have a capsule of placebo and a capsule of fish oil a day.
The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
This study is planned with the primary objective of developing a database containing patient-reported information that may be used to understand and increase awareness of the impact that moderate-to-severe plaque psoriasis can have on both daily life and life in general from a patient's perspective. This is a multicenter observational (no drug given to the patient) patient narrative study. The duration of study is 16 weeks and includes adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The study investigators are dermatologists who treat patients with moderate-to-severe plaque psoriasis. The study includes a screening visit 2 weeks before Week 0 (baseline). Patients will be evaluated at screening for current or peak historical physician's global assessment (PGA) response (range 0-5). Patients will provide narratives at the Week 0 (baseline) visit and may add additional information at an interval visit or at the end of the study on Week 16. Photography will be performed at Week 0 and at the end of study at Week 16. Additional photographs will be taken if there is any change in disease status (e.g., disease improvement or worsening, change in treatment) occurring prior to the end of the study. Between Week 0 and Week 16, patients may return to the study site for 1 interval visit at the first clinically significant change in disease status, if applicable. The Week 16 final assessment may be conducted as a telephone follow-up for patients who have had an interval visit between Week 0 and Week 16. If the patient did not return to the study site for an interval visit, the patient will return to the study site for a visit at Week 16. All assessments specified for the interval visit will be performed at Week 16. All patients will have the following data collected: PGA score, area of body involved, body surface area percent (BSA%, calculates percent of body surface area affected with psoriasis), Psoriasis Area and Severity Index (PASI) de-identified photographs, adverse events, and patient narratives. The information will be collected de-identified. Study materials (e.g., demographic and disease characteristic forms, narratives, and photographs) will be coded using a unique patient identification (ID) number. Only de-identified information will be available to the Sponsor and related study personnel.
Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.